li001

A new study reports a promising cell therapy for osteosarcoma, a bone cancer that is especially difficult to treat once it spreads. While survival rates for localized disease are about 70%, they fall below 30% when the cancer metastasizes, most often to the lungs. Treatment options have remained largely unchanged for decades, relying on surgery

A new study reports a promising cancer treatment strategy using a peptide called 1H13, designed to target survivin—a protein that helps cancer cells avoid death. Survivin is highly expressed in tumors but largely absent in normal adult tissues, making it an attractive therapeutic target. Previous attempts to block survivin have had limited success, but this

Emerging strategies in renal cell carcinoma are focusing on new drugs and personalized approaches to improve patient outcomes. Next-generation kinase inhibitors like Zanzalintinib show promise with high disease control rates in early trials. The Phase 3 STELLAR-304 study is testing it with Nivolumab as frontline therapy for non-clear cell RCC. Hypoxia-inducible factor (HIF)-2α inhibitors are

Positive results from the Phase 3 TALAPRO-3 trial show that a new combination therapy can significantly delay disease progression in patients with metastatic castration-sensitive prostate cancer who carry HRR gene mutations. The study evaluated Talazoparib combined with Enzalutamide in patients whose cancer has spread but still responds to hormone therapy. This group represents about 25%